phrykt

Neuphoria Therapeutics Inc. (NEUP): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of NEUP were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No NEUP insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

NEUP short interest

Low short interest. 0.2% of NEUP shares are sold short: about 1 share in 437. Over the last 12 reports the number of shares short went down 37%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 12,377 NEUP shares were sold short, 0.2% of the shares outstanding, up 92.5% from the report before. At the average daily volume of 37,998 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

0.23%May 15Oct 301.38%

Days to cover

1.0May 15Oct 301.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202612,3770.23%+93%37,9981.0
Oct 15, 20266,4290.12%-68%16,4471.0
Sep 30, 202620,0220.37%-19%12,4241.6
Sep 15, 202624,7130.46%-62%20,2041.2
Aug 31, 202664,6411.20%+54%67,6951.0
Aug 14, 202642,0340.78%-36%28,8321.5
Jul 31, 202665,5381.21%+327%638,7201.0
Jul 15, 202615,3340.28%-3%109,7471.0
Jun 30, 202615,8310.29%-31%78,3091.0
Jun 15, 202623,0290.43%-37%76,1961.0
May 29, 202636,8350.68%+88%59,8271.0
May 15, 202619,5980.36%-57%28,0891.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Neuphoria Therapeutics company events

Neuphoria Therapeutics filed 6 reports on Form 8-K in the last 12 months, 2 of them about an important change (control, listing). The latest was on Oct 23, 2026.

  1. Oct 23, 2026AgreementThe Board of Directors of Neuphoria Therapeutics Inc., a Delaware corporation, entered into Amendment No. 1 to the Rights Agreement, dated as of October 27, 2025, by and between the Company and Computershare Trust Company, N.A., as Rights Agent (the “Original Rights Agreement,” and as amended by… Filing
  2. Jul 24, 2026ControlTo the extent required by this Item, the information included in Item 1.01 of this Current Report is incorporated herein by reference. Filing
  3. May 26, 2026AnnouncementNeuphoria Therapeutics Inc. received a revenue distribution payment of AUD $1.416M from its participation in the former Cancer Therapeutics Cooperative Research Centre (CTx CRC) related to the Company’s licensing of the KAT6 program to Pfizer Inc. following the initiation of dosing of the first… Filing
  4. Jan 8, 2026AgreementAs previously announced on December 16, 2022 in a Current Report on Form 6-K filed by Bionomics Ltd. (now known as Neuphoria Therapeutics Inc., or the “Company”), the Company had appointed Spyridon “Spyros” Papapetropoulos, M.D. as President and Chief Executive Officer pursuant to the terms of that… Filing
  5. Dec 18, 2025ListingNotice of Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Filing
  6. Dec 17, 2025VoteReported shareholder vote results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Neuphoria Therapeutics financials

Famous investors that hold NEUP

1 of the 50 well-known investors we track reported holding NEUP in their latest 13F filing. The largest position is Ken Griffin's, worth $157K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202644,045$157K0.0%-39%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named NEUP in the last 120 days.

FiledHolderFormStake
Oct 5, 2026AdvisorShares Trust13G5.8%
Oct 5, 2026AdvisorShares Trust13G5.8%

Questions about Neuphoria Therapeutics Inc. (NEUP) stock

Are NEUP insiders buying or selling?

No NEUP insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in NEUP?

As of Oct 30, 2026, 12,377 NEUP shares were sold short, 0.2% of the shares outstanding, up 92.5% from the report before. At the average daily volume of 37,998 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold NEUP?

1 of the 50 well-known investors we track reported NEUP in their latest 13F filing, including Ken Griffin. The largest position is worth $157K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.